Kennedy R. Lees
University of Glasgow
467 Papers
3.9K Citations
Kennedy R. Lees is an academic researcher from University of Glasgow. The author has contributed to research in topics: Stroke & Medicine. The author has an hindex of 86, co-authored 455 publications. Previous affiliations of Kennedy R. Lees include Ludwig Maximilian University of Munich & Cedars-Sinai Medical Center.
Chat about Author
Papers
A multicentre observational study of presentation and early assessment of acute stroke
TL;DR: Delays in patients arriving at hospital with suspected stroke can be reduced by the increased use of emergency services and their management can be improved by expediting medical evaluation and performing computed tomography early.
Preoperative stroke and outcomes after coronary artery bypass graft surgery.
Alex Bottle,Abdul Mozid,Hilary P. Grocott,Matthew Walters,Kennedy R. Lees,Paul Aylin,Robert D. Sanders +6 more
TL;DR: The authors found no evidence that more recent preoperative stroke predisposed patients undergoing CABG surgery to suffer postoperative stroke, death, or prolonged length of stay, and found the combination of prior stroke and myocardial infarction substantially increased perioperative risk.
Predictors of Early Cardiac Morbidity and Mortality After Ischemic Stroke
Jane F. Prosser,Lachlan MacGregor,Kennedy R. Lees,Hans-Christoph Diener,Werner Hacke,Stephen M. Davis +5 more
TL;DR: Serious cardiac events are common in the acute period after stroke and patients at highest risk are identifiable and may benefit from more aggressive strategies to improve survival.
Xanthine oxidase inhibition for the improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST) - Protocol for a randomised double blind placebo-controlled clinical trial.
Jesse Dawson,Niall M. Broomfield,Krishna A Dani,David Alexander Dickie,Alex S. F. Doney,Kirsten P. Forbes,Graeme Houston,Sharon Kean,Kennedy R. Lees,Alex McConnachie,Keith W. Muir,Terry J Quinn,Allan D. Struthers,Matthew Walters +13 more
TL;DR: If white matter hyperintensity progression is reduced, allopurinol could be an effective preventative treatment for patients with ischaemic stroke and clinical endpoint studies would be needed.
Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention
Maurizio Paciaroni,Giancarlo Agnelli,Valeria Caso,Giorgio Silvestrelli,David J. Seiffge,Stefan T. Engelter,Gian Marco De Marchis,Alexandros A Polymeris,Marialuisa Zedde,Shadi Yaghi,Patrik Michel,Ashraf Eskandari,Kateryna Antonenko,Sung Il Sohn,Manuel Cappellari,Tiziana Tassinari,Rossana Tassi,Luca Masotti,Aristeidis H. Katsanos,Sotirios Giannopoulos,Monica Acciarresi,Andrea Alberti,Michele Venti,Maria Giulia Mosconi,Maria Cristina Vedovati,Patrizia Pierini,Michela Giustozzi,Enrico Maria Lotti,George Ntaios,Odysseas Kargiotis,Serena Monaco,Piergiorgio Lochner,Fabio Bandini,Chrysoula Liantinioti,Lina Palaiodimou,Azmil H. Abdul-Rahim,Kennedy R. Lees,Michelangelo Mancuso,Leonardo Pantoni,Silvia Rosa,Pierluigi Bertora,Silvia Galliazzo,Walter Ageno,Elisabetta Toso,Filippo Angelini,Alberto Chiti,Giovanni Orlandi,Licia Denti,Yuriy Flomin,Simona Marcheselli,Nicola Mumoli,Alexandra Rimoldi,Elena Pinuccia Verrengia,Erika Schirinzi,Massimo Del Sette,Panagiotis Papamichalis,Apostolos Komnos,Nemanja Popovic,Marija Zarkov,Alessandro Rocco,Marina Diomedi,Elisa Giorli,Alfonso Ciccone,Brian Mac Grory,Karen L. Furie,Bruno Bonetti,Valentina Saia,Francesca Guideri,Maurizio Acampa,Giuseppe Martini,Elisa Grifoni,Marina Padroni,Efstathia Karagkiozi,Kalliopi Perlepe,Konstantinos Makaritsis,Marina Mannino,Miriam Maccarrone,Leonardo Ulivi,Nicola Giannini,Elena Ferrari,Alessandro Pezzini,Boris Doronin,Vera Volodina,Antonio Baldi,Cataldo D'Amore,Dirk Deleu,Francesco Corea,Jukka Putaala,Paola Santalucia,Katiuscia Nardi,Angela Risitano,Danilo Toni,Georgios Tsivgoulis,Georgios Tsivgoulis,Georgios Tsivgoulis +94 more
TL;DR: In patients with AF treated with NOACs who had a cerebrovascular event, mostly but not exclusively of cardioembolic pathogenesis, off-label low dose, atrial enlargement, hyperlipidemia, and high CHA2DS2-VASc score were associated with increased risk of cerebroVascular events.